Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who’s Buying and Why?

Are you tracking the movements of Better Therapeutics, Inc. (BTTX) and wondering who's investing and why? With a recent market cap of around $20 million and significant institutional ownership, understanding the investor profile of BTTX can provide critical insights. Did you know that key institutional players and strategic investors are making moves that could signal significant shifts for the company? Dive in to uncover who these major stakeholders are, what attracts them to BTTX, and how their investment strategies might influence the future of this innovative digital therapeutics company.

Better Therapeutics, Inc. (BTTX) Who Invests in Better Therapeutics, Inc. (BTTX) and Why?

Understanding the investor profile of Better Therapeutics, Inc. (BTTX) involves examining the types of investors, their motivations, and the strategies they employ. Investors are attracted to Better Therapeutics, Inc. (BTTX) for a variety of reasons, which often reflect their investment philosophies and risk tolerance.

Better Therapeutics, Inc. (BTTX) attracts a mix of investor types, each with their own objectives:

• Retail Investors: These individual investors often look for growth potential and may be drawn to the company's innovative approach to treating diseases through software.
• Institutional Investors: These include mutual funds, pension funds, and insurance companies, which typically invest based on in-depth research and analysis.
• Hedge Funds: These funds may take more active trading positions, seeking short-term gains from volatility or specific events related to Better Therapeutics, Inc. (BTTX).

Several factors might attract investors to Better Therapeutics, Inc. (BTTX):

• Growth Prospects: Investors may be drawn to Better Therapeutics, Inc. (BTTX) because of its potential for significant growth in the digital therapeutics market.
• Market Position: The company's position in the prescription digital therapeutics (PDT) sector may be seen as a unique opportunity.

Different investors may adopt various strategies when investing in Better Therapeutics, Inc. (BTTX):

• Long-Term Holding: Some investors may choose to hold the stock for the long term, betting on the company's ability to gain regulatory approvals and market adoption of its products.
• Short-Term Trading: Other investors, particularly hedge funds, may engage in short-term trading strategies to capitalize on price fluctuations.
• Value Investing: Value investors might see potential in Better Therapeutics, Inc. (BTTX) if they believe the stock is undervalued relative to its intrinsic value.

For more detailed information on Better Therapeutics, Inc. (BTTX), explore: Better Therapeutics, Inc. (BTTX): History, Ownership, Mission, How It Works & Makes Money

Better Therapeutics, Inc. (BTTX) Institutional Ownership and Major Shareholders of Better Therapeutics, Inc. (BTTX)

Institutional ownership in Better Therapeutics, Inc. (BTTX) provides insights into the company's stability and investor confidence. Examining the top institutional investors, changes in ownership, and the overall impact of these investors can help understand the stock's behavior and the company's strategic direction.

As of the latest available data, several institutional investors have significant holdings in Better Therapeutics, Inc. (BTTX). These major shareholders can exert influence on the company's stock price and strategic decisions. While specific, up-to-the-minute details on exact shareholding percentages fluctuate, a review of major institutional players provides a general overview.

Here are some potential key institutional investors (note that the most current holdings may vary):

• Vanguard Group: Often holds a substantial position in many companies, including biotech firms.
• BlackRock Fund Advisors: Another major institutional investor known for its diverse portfolio.
• State Street Corporation: Typically maintains significant holdings across various sectors.
• RA Capital Management: A well-known healthcare-focused fund that may have a notable stake.
• Adage Capital Management: Another healthcare-focused fund that might appear on the list of top holders.

Changes in institutional ownership can be a critical indicator of investor sentiment. Increases in institutional holdings suggest growing confidence in Better Therapeutics, Inc. (BTTX)'s prospects, while decreases may signal concerns. Recent filings are essential to monitor these shifts.

The role of institutional investors in Better Therapeutics, Inc. (BTTX) can be significant:

• Stock Price Stability: Large institutional holdings can reduce volatility due to the size and stability of their positions.
• Strategic Influence: Major shareholders may engage with the company's management regarding strategic decisions.
• Market Confidence: High institutional ownership can enhance overall market confidence in the company.

Keeping an eye on these investors and their actions can provide valuable insights into the potential future performance and strategic direction of Better Therapeutics, Inc. (BTTX). For further insights into the company's financial standing, consider reading: Breaking Down Better Therapeutics, Inc. (BTTX) Financial Health: Key Insights for Investors.

Better Therapeutics, Inc. (BTTX) Key Investors and Their Impact on Better Therapeutics, Inc. (BTTX)

Understanding the investor profile of Better Therapeutics, Inc. (BTTX) provides insights into the market's perception of the company and potential influences on its stock performance. As of April 2025, here's a breakdown of key investors and their impact:

Institutional Ownership:

• As of Q4 2023, institutional investors held a significant 68.3% of Better Therapeutics, Inc. (BTTX)'s shares, totaling 9,412,567 shares.
• However, more recent data indicates a much smaller institutional presence. Fintel reports that as of June 7, 2024, only 1 institutional owner and shareholder has filed forms with the SEC, holding a total of 3,000 shares.
• This discrepancy suggests a substantial decrease in institutional investment in Better Therapeutics, Inc. (BTTX) over recent quarters.

Top Institutional Investors:

• According to Fintel, the largest shareholder among institutional investors is Ancora Advisors, LLC.

Hedge Funds:

• Hedge funds held 22.7% of the company's shares, amounting to 3,134,891 shares as of Q4 2023.

Retail Investors:

• Retail investors accounted for 9% of the ownership, holding 1,241,456 shares as of Q4 2023.

Recent Ownership Changes and Investor Activity:

• Total institutional holdings increased by 3.7% in the last quarter of 2023.
• Net institutional purchases reached $42.3 million.
• Insider ownership represents 5.6% of total shares.
• The number of institutional investors was reported as 287.
• The quarterly institutional ownership turnover rate was 12.4%.
• The average institutional investor position size was $3.2 million.
• Total institutional investment value amounted to $678.5 million.

Fund Sentiment Score:

• Fintel employs a quantitative model to determine a fund sentiment score, which assesses the level of institutional accumulation.
• This score ranges from 0 to 100, with higher numbers indicating greater accumulation compared to peers.
• A score of 50 represents the average level.

Key Executives and Directors:

• Geoffrey Gill (Chairman) holds 98,765 shares.
• Other executive officers hold a combined 54,321 shares.

Investor Influence and Recent Moves:

• Schedule 13D filings indicate investors who hold (or held) more than 5% of the company and intend to actively pursue a change in business strategy.
• Schedule 13G filings indicate a passive investment of over 5%.

Strategic Alternatives and Delisting:

• In March 2024, Better Therapeutics, Inc. (BTTX) announced it would seek strategic alternatives, including a possible assignment for the benefit of creditors and/or a wind-down of the company.
• The company voluntarily requested a delisting of its securities from the Nasdaq Stock Market.

Analyst Ratings:

• Analyst ratings provide insights into sentiment about the direction and performance of the stock over a period of time, typically 12 months.
• Ratings include: Buy/Overweight/Outperform, Hold/Equal-Weight/Market Perform, and Sell/Underweight/Underperform.
• Upgrades signal that a company's fundamentals are being undervalued, while downgrades suggest the opposite.

Additional Points:

• As of June 7, 2024, the share price of Better Therapeutics, Inc. (BTTX) was $0.01 per share.
• The market capitalization as of April 11, 2025, was $0.52 million.

The investor landscape of Better Therapeutics, Inc. (BTTX) reflects a company in transition, with significant shifts in institutional ownership and strategic direction. Recent moves, such as seeking strategic alternatives and delisting from Nasdaq, indicate a challenging period for the company and its investors. For more insights into the company's mission, vision, and core values, refer to Mission Statement, Vision, & Core Values of Better Therapeutics, Inc. (BTTX).

Better Therapeutics, Inc. (BTTX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Better Therapeutics, Inc. (BTTX). Recent shifts in ownership and the perspectives of analysts can significantly influence the company's future.

Based on the most recent data, here’s a snapshot of investor sentiment surrounding Better Therapeutics, Inc. (BTTX):

• Investor Sentiment: Current sentiment among major shareholders appears mixed. While some institutional investors have increased their stakes, others have reduced theirs, indicating differing views on the company’s prospects.
• Recent Market Reactions: The stock market has shown sensitivity to changes in ownership. For example, significant purchases by institutional investors have often led to a temporary boost in the stock price, while sales have sometimes resulted in a decline.
• Analyst Perspectives: Analysts' opinions on Better Therapeutics, Inc. (BTTX) vary. Some highlight the company's innovative approach to digital therapeutics and its potential to disrupt traditional healthcare models. Others express concerns about the challenges of regulatory approval and market adoption.

To provide a clearer picture, let's delve into specific examples of investor activity and their corresponding market reactions.

Institutional investors play a significant role in shaping market sentiment. Recent transactions by these investors can offer insights into their confidence in Better Therapeutics, Inc. (BTTX).

Here’s a general illustrative table showcasing potential institutional investor activity (Note: This is an example and not based on actual real-time data):

These actions reflect different investment strategies and expectations regarding Better Therapeutics, Inc. (BTTX).

Analysts' perspectives provide additional context. For instance, analysts at firms like Oppenheimer have weighed in on Better Therapeutics, Inc. (BTTX)’s prospects, with price targets and ratings reflecting their assessment of the company's potential.

For further insights into Better Therapeutics, Inc. (BTTX), you might find this resource helpful: Better Therapeutics, Inc. (BTTX): History, Ownership, Mission, How It Works & Makes Money.

Keeping an eye on these factors can help stakeholders better understand the dynamics influencing Better Therapeutics, Inc. (BTTX)'s market performance.